Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is experiencing a positive outlook due to its recent market exclusivity announcement for Papzimeos in treating adult RRP, continued progress on its AdenoVerse portfolio, and the potential for label expansion opportunities. Additionally, the company's ongoing clinical trials and increasing patient enrollment numbers in its patient hub support a strong commercial launch and potential revenue growth. Despite potential risks in the clinical, regulatory, partnership, financial, and intellectual property areas, Precigen's strong presence at medical meetings and dedication to driving awareness and education for Papzimeos give confidence in the potential for success in the market.

Bears say

Precigen is experiencing financial growth, as shown by their increasing sales projections and confidence in reaching cash flow breakeven by 2026. However, the company's current financial performance and future prospects are dependent on its ability to successfully develop and commercialize its gene therapy platforms, which could face potential regulatory challenges and competition from other companies. Additionally, the company still has a significant amount of debt and negative cash flow, which could impact their ability to fund their research and development efforts.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.